NEWAMSTERDAM PHARMA CO NVNAMS
ASignal's systematic analysis rates NAMS as Bearish.
Reflects the latest available analysis · analyzed Oct 1, 2026
The case on NAMS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health with high cash reserves and zero debt-to-equity
- Current ratio of 9.03x indicates robust liquidity position
- MACD histogram is expanding positively, suggesting weakening bearish momentum
- Price above 20-day SMA, indicating short-term uptrend
- Negative operating margin at -1752.61%, indicating severe cost inefficiencies
- Negative return on equity (-36.81%) and return on assets (-20.11%)
- Revenue growth YoY at -80.70%, signaling significant top-line contraction
- Extremely high valuation metrics: price-to-sales at 405.56x, EV/revenue at 319.25x
- Negative operating and free cash flow
- Only two news sources available with no Reddit sentiment data
See the full verdict on NAMS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NAMS
Most investors never get a second opinion, let alone several. ASignal runs NAMS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.